Corning Incorporated vs Eli Lilly And Co — how do they compare? Corning Incorporated trades at $169.48 (market cap $137.12B), while Eli Lilly And Co trades at $1,193.59 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 7.9× Corning Incorporated's market cap, and Corning Incorporated pays the higher dividend (0.7%). Which is the better fit depends on your goals.
| GLW | LLY | |
|---|---|---|
Market Cap | $137.12B | $1.08T |
Sector | Technology | Health |
52-Week High | $255.79 | $1.24K |
52-Week Low | $64.52 | $639.43 |
Enterprise Value | $144.00B | $1.13T |
Dividend Yield | 0.7% | 0.57% |
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $157.74, down 4.8% in the last session amid broader market volatility. The stock shows strong fundamental momentum with three consecutive quarterly earnings beats and projected 2026 revenue growth to $17B. Technical indicators are mixed with a neutral overall signal while valuation metrics remain elevated with a P/E of 73.36. Recent analyst upgrades highlight AI infrastructure and optical communications growth potential.
GLW presents a compelling growth story driven by AI data center demand and optical communications expansion, though premium valuation requires flawless execution. Key risks include competitive pressures in photonics and sensitivity to technology spending cycles. With 57% analyst buy ratings and a $193.33 consensus target offering 23% upside, the stock warrants consideration for growth-oriented investors despite near-term volatility.
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Trailing returns across standard periods
Latest headlines on both assets
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →